Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

The new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.

The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or ...

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used ...

GSK (NYSE:GSK) announced on Thursday that EU regulators approved two combination therapies involving its antibody drug ...

The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns ...

And other biotech news brought to you by The Readout.

The British drugmaker was trying to revive the drug, which was pulled from U.S. markets in 2022 after failing a late-stage ...

GSK, at the request of the FDA, is set to withdraw the U.S. marketing authorization for Blenrep. The FDA's request comes after the failure of a phase III confirmatory study, DREAMM-3.

BLENREP was developed and will be commercialized by GSK. The approval triggers a $20 million milestone payment and entitles Seattle Genetics to royalties on BLENREP product sales.

FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Contacts GSK Inquiries: Media Inquiries: Simon Steel +44 (0) 20 ...